YDESW

YD Bio Ltd

• PUBT·04/30 21:46

  YD Bio FY25 net loss widens to $8.3 million; revenue rises 17% to $596,817

• Reuters·04/02 20:02

  YD Bio files Form 3 as director Lu Shao-Ta reports no beneficial ownership

• Reuters·04/02 11:27

  YD Bio files Form 3 as director Kochi Chang reports no beneficial ownership

• Reuters·03/30 21:30

  YD Bio files Form 3; director Jerry Yin-Chia Lee reports no securities owned

• Reuters·03/27 20:05

  YD Bio files initial beneficial ownership statement; Chief Medical Officer and director Zhang Bo-Xiang reports 31,141 ordinary shares

• Reuters·03/26 20:02

  YD Bio files initial beneficial ownership statement; CFO Edmund Hen reports no securities beneficially owned

• Reuters·03/18 14:51

  YD Bio Limited files Form 3 as CEO Ethan Shen reports 54.34 million ordinary shares owned

• Reuters·03/17 12:02

  YD Bio outlines plan to integrate cancer detection with dendritic cell immunotherapy by 2027

• Reuters·02/25 18:48

  BUZZ-U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara

• Reuters·02/25 15:46

  BUZZ-U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin

• Reuters·02/25 14:39

  BUZZ-U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight

• Reuters·02/25 13:02

  YD Bio USA Partners With YC Biotech to Build Taiwan-U.S. Dual-Core FDA Regulatory Platform

• Reuters·02/25 13:00

  YD BIO LTD: YD BIO USA WILL SERVE AS YC BIOTECH'S EXCLUSIVE U.S. AGENT AND FORMAL LIAISON WITH FDA

• Reuters·02/25 13:00

  YD BIO LTD - PARTNERSHIP COVERS FDA-RELATED PROJECTS INCLUDING IND, NDA, BLA SUBMISSIONS

• Reuters·02/25 13:00

  YD BIO LIMITED ANNOUNCES STRATEGIC PARTNERSHIP WITH YC BIOTECH CO., LTD. TO ESTABLISH A TAIWAN-U.S. DUAL-CORE REGULATORY PLATFORM